JP6605957B2 - 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 - Google Patents

生体系におけるプロテアーゼ活性を検出するための組成物及び方法 Download PDF

Info

Publication number
JP6605957B2
JP6605957B2 JP2015551784A JP2015551784A JP6605957B2 JP 6605957 B2 JP6605957 B2 JP 6605957B2 JP 2015551784 A JP2015551784 A JP 2015551784A JP 2015551784 A JP2015551784 A JP 2015551784A JP 6605957 B2 JP6605957 B2 JP 6605957B2
Authority
JP
Japan
Prior art keywords
activatable antibody
antibody
certain embodiments
target
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015551784A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505138A (ja
JP2016505138A5 (OSRAM
Inventor
バジルジェバ オルガ
メアリー メネンデズ エリザベス−エドナ
Original Assignee
シトムクス セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シトムクス セラピューティクス，インコーポレイティド filed Critical シトムクス セラピューティクス，インコーポレイティド
Publication of JP2016505138A publication Critical patent/JP2016505138A/ja
Publication of JP2016505138A5 publication Critical patent/JP2016505138A5/ja
Application granted granted Critical
Publication of JP6605957B2 publication Critical patent/JP6605957B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015551784A 2013-01-04 2014-01-03 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 Active JP6605957B2 (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201361749212P 2013-01-04 2013-01-04
US201361749220P 2013-01-04 2013-01-04
US61/749,212 2013-01-04
US61/749,220 2013-01-04
US201361749529P 2013-01-07 2013-01-07
US201361749486P 2013-01-07 2013-01-07
US61/749,486 2013-01-07
US61/749,529 2013-01-07
US201361755810P 2013-01-23 2013-01-23
US61/755,810 2013-01-23
US201361763237P 2013-02-11 2013-02-11
US61/763,237 2013-02-11
US201361830940P 2013-06-04 2013-06-04
US61/830,940 2013-06-04
US201361897659P 2013-10-30 2013-10-30
US61/897,659 2013-10-30
PCT/US2014/010216 WO2014107599A2 (en) 2013-01-04 2014-01-03 Compositions and methods for detecting protease activity in biological systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019190445A Division JP7001652B2 (ja) 2013-01-04 2019-10-17 生体系におけるプロテアーゼ活性を検出するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2016505138A JP2016505138A (ja) 2016-02-18
JP2016505138A5 JP2016505138A5 (OSRAM) 2017-02-09
JP6605957B2 true JP6605957B2 (ja) 2019-11-13

Family

ID=51062553

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015551784A Active JP6605957B2 (ja) 2013-01-04 2014-01-03 生体系におけるプロテアーゼ活性を検出するための組成物及び方法
JP2019190445A Active JP7001652B2 (ja) 2013-01-04 2019-10-17 生体系におけるプロテアーゼ活性を検出するための組成物及び方法
JP2021209234A Active JP7223832B2 (ja) 2013-01-04 2021-12-23 生体系におけるプロテアーゼ活性を検出するための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019190445A Active JP7001652B2 (ja) 2013-01-04 2019-10-17 生体系におけるプロテアーゼ活性を検出するための組成物及び方法
JP2021209234A Active JP7223832B2 (ja) 2013-01-04 2021-12-23 生体系におけるプロテアーゼ活性を検出するための組成物及び方法

Country Status (9)

Country Link
US (4) US10261083B2 (OSRAM)
EP (1) EP2941643A4 (OSRAM)
JP (3) JP6605957B2 (OSRAM)
CN (2) CN105008918A (OSRAM)
AU (2) AU2014204015A1 (OSRAM)
CA (1) CA2896282C (OSRAM)
HK (1) HK1210831A1 (OSRAM)
RU (1) RU2015132436A (OSRAM)
WO (1) WO2014107599A2 (OSRAM)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2403964B1 (en) 2009-03-02 2021-09-08 Massachusetts Institute of Technology Methods and products for in vivo enzyme profiling
US10006916B2 (en) 2011-03-15 2018-06-26 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
HK1210831A1 (en) 2013-01-04 2016-05-06 Cytomx Therapeutics Inc. Compositions and methods for detecting protease activity in biological systems
KR20160018579A (ko) 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
CN118010994A (zh) 2013-06-07 2024-05-10 麻省理工学院 基于亲和力检测配体编码的合成性生物标记物
RU2727836C2 (ru) * 2013-07-25 2020-07-24 Сайтомкс Терапьютикс, Инк. Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
CN118146306A (zh) * 2013-09-25 2024-06-07 西托姆克斯治疗公司 基质金属蛋白酶底物和其它可切割部分及其使用方法
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
JP6835586B2 (ja) 2014-01-31 2021-02-24 シトムクス セラピューティクス，インコーポレイティド マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
BR112017001579A2 (pt) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
WO2016028805A1 (en) * 2014-08-18 2016-02-25 Adrastia Biotech Systems and methods of detecting solid tumor cancer
ES2789351T3 (es) * 2015-01-13 2020-10-26 Hope City Máscaras de enlace peptídico de proteínas de unión a CTLA4
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
CN107849133B (zh) 2015-05-04 2022-08-23 西托姆克斯治疗公司 抗cd166抗体、可活化抗cd166抗体及其使用方法
HUE050750T2 (hu) 2015-05-29 2021-01-28 Agenus Inc CTLA-4 elleni antitestek és eljárások alkalmazásukra
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3313874B1 (en) * 2015-06-26 2021-03-10 University of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
CN106519037B (zh) * 2015-09-11 2019-07-23 科济生物医药（上海）有限公司 可活化的嵌合受体
JP7073258B2 (ja) 2015-11-19 2022-05-23 レビトープ リミテッド 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完
SG11201806134SA (en) 2016-01-27 2018-08-30 Oncorus Inc Oncolytic viral vectors and uses thereof
US10358496B2 (en) 2016-03-01 2019-07-23 Ralf Kleef Low dose immune checkpoint blockade in metastatic cancer
WO2017177115A1 (en) 2016-04-08 2017-10-12 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
US11428689B2 (en) 2016-05-05 2022-08-30 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
CN110036034A (zh) 2016-12-09 2019-07-19 西雅图遗传学公司 卷曲螺旋掩蔽的二价抗体
AU2018248327B2 (en) 2017-04-07 2024-10-10 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
BR112020000766A2 (pt) 2017-07-14 2020-07-21 Cytomx Therapeutics, Inc. anticorpos anti-cd166 e seus usos
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
BR112020007309A2 (pt) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
CA3083946A1 (en) 2017-12-01 2019-06-06 Seattle Genetics, Inc. Cd47 antibodies and uses thereof for treating cancer
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
US11054428B2 (en) 2018-03-05 2021-07-06 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
US20210020264A1 (en) 2018-03-20 2021-01-21 Cytomx Therapeutics, Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
JP7497340B2 (ja) 2018-05-14 2024-06-10 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン１２ポリペプチド及びその使用方法
FI3794024T3 (fi) 2018-05-14 2023-08-10 Werewolf Therapeutics Inc Aktivoitavia interleukiini-2-polypeptidejä ja niiden käyttömenetelmiä
US20210322508A1 (en) * 2018-08-13 2021-10-21 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2019394972A1 (en) 2018-12-06 2021-06-03 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
CN113490688B (zh) 2018-12-26 2025-07-29 希望之城公司 可活化的被掩蔽的抗ctla4结合蛋白质
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
WO2020236679A1 (en) * 2019-05-17 2020-11-26 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
WO2020247574A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Methods of purifying masked antibodies
TW202112354A (zh) 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 遮蔽抗體調配物
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
WO2021207657A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
CN111830254B (zh) * 2020-07-29 2022-07-26 武汉生之源生物科技股份有限公司 一种基质金属蛋白酶-3测定试剂盒及其制备方法
CN114859042B (zh) * 2021-02-03 2023-11-03 广东菲鹏生物有限公司 一种鉴别结合突变型抗原的抗体的方法及试剂
US20240352080A1 (en) 2021-07-14 2024-10-24 Seagen Inc. Antibody Masking Domains
US20250116658A1 (en) * 2021-07-26 2025-04-10 Georgia Tech Research Corporation Compositions and methods for in vivo protease profiling by immune cell display
US20240384323A1 (en) * 2021-08-30 2024-11-21 Cytomx Therapeutics, Inc. Method for determining protease activity in a biological sample
US20240376200A1 (en) 2021-09-24 2024-11-14 Seagen Inc. Improved Antibody Masking Domains
WO2023168239A2 (en) * 2022-03-01 2023-09-07 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb ligands and blocking antibodies
EP4508086A1 (en) 2022-04-13 2025-02-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
EP3896076A1 (en) 2005-08-31 2021-10-20 The Regents of the University of California Cellular libraries of peptide sequences (clips) and methods of using the same
CA2645347A1 (en) 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
US9156914B2 (en) * 2006-12-19 2015-10-13 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2010077643A1 (en) 2008-12-08 2010-07-08 Tegopharm Corporation Masking ligands for reversible inhibition of multivalent compounds
US20110178279A1 (en) * 2009-08-03 2011-07-21 Williams John C Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
IN2014MN02164A (OSRAM) 2012-04-27 2015-08-28 Cytomx Therapeutics Inc
SG11201408554QA (en) * 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
HK1210831A1 (en) 2013-01-04 2016-05-06 Cytomx Therapeutics Inc. Compositions and methods for detecting protease activity in biological systems

Also Published As

Publication number Publication date
JP7001652B2 (ja) 2022-02-21
WO2014107599A3 (en) 2014-09-04
HK1210831A1 (en) 2016-05-06
US11035859B2 (en) 2021-06-15
AU2018250437B2 (en) 2020-09-03
RU2015132436A (ru) 2017-02-09
US20140255313A1 (en) 2014-09-11
CN112162094A (zh) 2021-01-01
JP2016505138A (ja) 2016-02-18
CA2896282A1 (en) 2014-07-10
JP7223832B2 (ja) 2023-02-16
JP2022036134A (ja) 2022-03-04
CN105008918A (zh) 2015-10-28
US20240337658A1 (en) 2024-10-10
WO2014107599A2 (en) 2014-07-10
US11867695B2 (en) 2024-01-09
US10261083B2 (en) 2019-04-16
CA2896282C (en) 2021-07-20
EP2941643A2 (en) 2015-11-11
US20200025761A1 (en) 2020-01-23
AU2018250437A1 (en) 2018-11-15
JP2020098195A (ja) 2020-06-25
US20210382053A1 (en) 2021-12-09
AU2014204015A1 (en) 2015-07-09
EP2941643A4 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
JP7223832B2 (ja) 生体系におけるプロテアーゼ活性を検出するための組成物及び方法
US12139543B2 (en) Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR
JP7781254B2 (ja) マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
US20240398998A1 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
RU2715232C2 (ru) Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
JP2020532509A (ja) 活性化可能抗ｃｄ１６６抗体およびその使用方法
CN107531758A (zh) 基质金属蛋白酶可切割且丝氨酸蛋白酶可切割底物及其使用方法
BR122023022856A2 (pt) Polipeptídeo isolado compreendendo substratos de matriptase e de ativador do plasminogênio u e outras porções cliváveis, composição farmacêutica compreendendo o dito polipeptídeo, bem como métodos para produzir e fabricar um polipeptídeo isolado compreendendo uma porção clivável e uso e quantidade terapeuticamente eficaz da dita composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191017

R150 Certificate of patent or registration of utility model

Ref document number: 6605957

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250